Therapeutic Approach

Archive: March, 2013

Ritter Pharmaceuticals Encouraged by Meeting with FDA: Feedback Provides Clarity for Clinical Development Plans

LOS ANGELES, CALIF., MARCH 20, 2013 — Ritter Pharmaceuticals today reported that it is preparing to move forward with the design and implementation of the next stage of clinical trials to advance the development of RP-G28, the first therapeutic agent aimed at treating Lactose Intolerance.  Company representatives recently met with teams from the FDA to […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD